Literature DB >> 26243574

A long-lasting protective immunity against chronic toxoplasmosis in mice induced by recombinant rhoptry proteins encapsulated in poly (lactide-co-glycolide) microparticles.

Ying Xu1,2, Nian-Zhang Zhang1, Meng Wang1, Hu Dong1, Sheng-Yong Feng1, Hui-Chen Guo3, Xing-Quan Zhu4,5.   

Abstract

Toxoplasma gondii infection in humans and animals is a worldwide zoonosis. Prevention and control of toxoplasmosis based on vaccination is one of the promising strategies. In the present study, recombinant T. gondii rhoptry proteins 38 and 18 (TgROP38 and TgROP18) were encapsulated into poly (lactide-co-glycolide) (PLG) (1:1), respectively, to obtain the stable water-in-oil-in-water double emulsion. Female Kunming mice were then immunized with the protein vaccines twice at a 2-week interval. Eight weeks after the second immunization, 10 mice from each group were challenged with T. gondii PRU strain (genotype II). The entrapment rates of PLG-rROP38 and PLG-rROP18 ranged from 65.5 to 77.7% and 58.1 to 72.3%, respectively. Immunization of mice with rROP38 and rROP18 proteins encapsulated into PLG microparticles elicited strongly humoral and cell-mediated responses against T. gondii, associated with relatively high levels of total IgG, IgG2a isotype, and IFN-γ, as well as the mixed Th1/Th2 immunity responses. Immunization with various protein vaccines induced significant reduction of the brain cysts after chronic infection with the T. gondii PRU strain, and the most effective protection was achieved in the PLG-rROP38-rROP18-immunized mice, with a cyst reduction of 81.3%. The findings of the present study indicated that recombinant rhoptry antigens encapsulated in PLG could maintain the protein immunogenicity in an extended period and elicit effective protection against chronic T. gondii infection, which has implications for the development of long-lasting vaccines against chronic toxoplasmosis in animals.

Entities:  

Keywords:  Poly (lactide-co-glycolide) microparticles; Protective immunity; Rhoptry protein 18; Rhoptry protein 38; Toxoplasma gondii; Toxoplasmosis

Mesh:

Substances:

Year:  2015        PMID: 26243574     DOI: 10.1007/s00436-015-4652-3

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  38 in total

Review 1.  Kiss and spit: the dual roles of Toxoplasma rhoptries.

Authors:  John C Boothroyd; Jean-Francois Dubremetz
Journal:  Nat Rev Microbiol       Date:  2008-01       Impact factor: 60.633

Review 2.  Vaccines against Toxoplasma gondii: challenges and opportunities.

Authors:  Erik Jongert; Craig W Roberts; Nicola Gargano; Elisabeth Förster-Waldl; Elisabeth Förster-Wald; Eskild Petersen
Journal:  Mem Inst Oswaldo Cruz       Date:  2009-03       Impact factor: 2.743

3.  Enhancement of protective immune response to recombinant Toxoplasma gondii ROP18 antigen by ginsenoside Re.

Authors:  Daofeng Qu; Jianzhong Han; Aifang Du
Journal:  Exp Parasitol       Date:  2013-07-26       Impact factor: 2.011

Review 4.  Vaccination as a control strategy against the coccidial parasites Eimeria, Toxoplasma and Neospora.

Authors:  E A Innes; A N Vermeulen
Journal:  Parasitology       Date:  2006       Impact factor: 3.234

5.  Functional characterization of in vivo effector CD4(+) and CD8(+) T cell responses in acute Toxoplasmosis: an interplay of IFN-gamma and cytolytic T cells.

Authors:  Erik Jongert; Arnaud Lemiere; Jo Van Ginderachter; Stéphane De Craeye; Kris Huygen; Sushila D'Souza
Journal:  Vaccine       Date:  2010-01-29       Impact factor: 3.641

Review 6.  The secreted kinase ROP18 defends Toxoplasma's border.

Authors:  Sarah J Fentress; L David Sibley
Journal:  Bioessays       Date:  2011-07-20       Impact factor: 4.345

Review 7.  Epidemiology of and diagnostic strategies for toxoplasmosis.

Authors:  Florence Robert-Gangneux; Marie-Laure Dardé
Journal:  Clin Microbiol Rev       Date:  2012-04       Impact factor: 26.132

8.  Foot-and-mouth disease virus-like particles produced by a SUMO fusion protein system in Escherichia coli induce potent protective immune responses in guinea pigs, swine and cattle.

Authors:  Hui-Chen Guo; Shi-Qi Sun; Ye Jin; Shun-Li Yang; Yan-Quan Wei; De-Hui Sun; Shuang-Hui Yin; Jun-Wu Ma; Zai-Xin Liu; Jian-Hong Guo; Jian-Xun Luo; Hong Yin; Xiang-Tao Liu; Ding Xiang Liu
Journal:  Vet Res       Date:  2013-07-04       Impact factor: 3.683

9.  Evaluation of immuno-efficacy of a novel DNA vaccine encoding Toxoplasma gondii rhoptry protein 38 (TgROP38) against chronic toxoplasmosis in a murine model.

Authors:  Ying Xu; Nian-Zhang Zhang; Qi-Dong Tan; Jia Chen; Jing Lu; Qian-Ming Xu; Xing-Quan Zhu
Journal:  BMC Infect Dis       Date:  2014-09-30       Impact factor: 3.090

10.  Does Toxoplasma gondii infection affect the levels of IgE and cytokines (IL-5, IL-6, IL-10, IL-12, and TNF-alpha)?

Authors:  Joanna Matowicka-Karna; Violetta Dymicka-Piekarska; Halina Kemona
Journal:  Clin Dev Immunol       Date:  2009-05-25
View more
  9 in total

1.  Induction of specific humoral immune response in mice immunized with ROP18 nanospheres from Toxoplasma gondii.

Authors:  Habibun Nabi; Imran Rashid; Nisar Ahmad; Aneela Durrani; Haroon Akbar; Saher Islam; Amna Arshad Bajwa; Wasim Shehzad; Kamran Ashraf; Nyla Imran
Journal:  Parasitol Res       Date:  2016-10-27       Impact factor: 2.289

Review 2.  PLGA Nanoparticles as an Efficient Platform in Protein Vaccines Against Toxoplasma gondii.

Authors:  Mojgan Allahyari
Journal:  Acta Parasitol       Date:  2022-01-11       Impact factor: 1.440

Review 3.  Integrating Biomaterials and Immunology to Improve Vaccines Against Infectious Diseases.

Authors:  Lampouguin Yenkoidiok-Douti; Christopher M Jewell
Journal:  ACS Biomater Sci Eng       Date:  2020-01-12

4.  Evaluation of Protective Immune Responses Induced by Recombinant TrxLp and ENO2 Proteins against Toxoplasma gondii Infection in BALB/c Mice.

Authors:  Meng Wang; Xiao-Yu Yang; Nian-Zhang Zhang; De-Lin Zhang; Xing-Quan Zhu
Journal:  Biomed Res Int       Date:  2016-10-10       Impact factor: 3.411

5.  Chitosan Microsphere Used as an Effective System to Deliver a Linked Antigenic Peptides Vaccine Protect Mice Against Acute and Chronic Toxoplasmosis.

Authors:  Jingjing Guo; Xiahui Sun; Huiquan Yin; Ting Wang; Yan Li; Chunxue Zhou; Huaiyu Zhou; Shenyi He; Hua Cong
Journal:  Front Cell Infect Microbiol       Date:  2018-05-23       Impact factor: 5.293

Review 6.  Sixty Years (1957-2017) of Research on Toxoplasmosis in China-An Overview.

Authors:  Ming Pan; Congcong Lyu; Junlong Zhao; Bang Shen
Journal:  Front Microbiol       Date:  2017-09-25       Impact factor: 5.640

7.  Protective Effect Against Toxoplasmosis in BALB/c Mice Vaccinated With Recombinant Toxoplasma gondii MIF, CDPK3, and 14-3-3 Protein Cocktail Vaccine.

Authors:  Fang Liu; Minmin Wu; Jie Wang; Hongyang Wen; Ran An; Haijian Cai; Li Yu; Jilong Shen; Lijian Chen; Jian Du
Journal:  Front Immunol       Date:  2021-12-22       Impact factor: 7.561

8.  Toxoplasma gondii Proteasome Subunit Alpha Type 1 with Chitosan: A Promising Alternative to Traditional Adjuvant.

Authors:  Zhengqing Yu; Wenxi Ding; Muhammad Tahir Aleem; Junzhi Su; Junlong Liu; Jianxun Luo; Ruofeng Yan; Lixin Xu; Xiaokai Song; Xiangrui Li
Journal:  Pharmaceutics       Date:  2021-05-19       Impact factor: 6.321

Review 9.  Calcium-dependent protein kinases are potential targets for Toxoplasma gondii vaccine.

Authors:  Masoud Foroutan; Fatemeh Ghaffarifar
Journal:  Clin Exp Vaccine Res       Date:  2018-01-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.